Chr. Hansen is followed by a number of financial analysts that regularly publish commentary, financial forecasts and recommendations on the stock. Once a quarter, Chr. Hansen compiles a consensus which reflects the average of all available estimates on Chr. Hansen’s future financials. The consensus is collected – without any claim of being exhaustive – and published on the website prior to quarterly results publication.
The Q4 2022/23 consensus was published here on October 10, 2023.
Consensus overview of Group estimates
| EUR m / % | Revenue | Organic growth | EBIT margin b.s.i. | FCF b.s.i.a. |
|---|---|---|---|---|
| Q4 2022/23 | 350 | 10.4% | 28.3% | |
| FY 2022/23 | 1,335 | 9.9% | 26.8% | 199 |
Further details such as estimates for our business areas, highest and lowest estimates as well as the number of inputs can be found in the below Excel file.
Chr. Hansen Q4 2022/23 consensus (Excel file)
Disclaimer: The consensus has been issued by Chr. Hansen for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding our revenues, earnings and business developments. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Chr. Hansen gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness.